• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

个体患者和人群水平抗 SARS-CoV-2 血清转化的动态。

Dynamics of anti-SARS-CoV-2 seroconversion in individual patients and at the population level.

机构信息

Regional Specialist Hospital in Wrocław, Research and Development Center, Wrocław, Poland.

Department of Family Medicine, Wroclaw Medical University, Wroclaw, Poland.

出版信息

PLoS One. 2022 Sep 9;17(9):e0274095. doi: 10.1371/journal.pone.0274095. eCollection 2022.

DOI:10.1371/journal.pone.0274095
PMID:36083875
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9462561/
Abstract

The immune response and specific antibody production in COVID-19 are among the key factors that determine both prognostics for individual patients and the global perspective for controlling the pandemics. So called "dark figure", that is, a part of population that has been infected but not registered by the health care system, make it difficult to estimate herd immunity and to predict pandemic trajectories. Here we present a follow up study of population screening for hidden herd immunity to SARS-CoV-2 in individuals who had never been positively diagnosed against SARS-CoV-2; the first screening was in May 2021, and the follow up in December 2021. We found that specific antibodies targeting SARS-CoV-2 detected in May as the "dark figure" cannot be considered important 7 months later due to their significant drop. On the other hand, among participants who at the first screening were negative for anti-SARS-CoV-2 IgG, and who have never been diagnosed for SARS-CoV-2 infection nor vaccinated, 26% were found positive for anti-SARS-CoV-2 IgG. This can be attributed to of the "dark figure" of the recent, fourth wave of the pandemic that occurred in Poland shortly before the study in December. Participants who were vaccinated between May and December demonstrated however higher levels of antibodies, than those who undergone mild or asymptomatic (thus unregistered) infection. Only 7% of these vaccinated participants demonstrated antibodies that resulted from infection (anti-NCP). The highest levels of protection were observed in the group that had been infected with SARS-CoV-2 before May 2021 and also fully vaccinated between May and December. These observations demonstrate that the hidden fraction of herd immunity is considerable, however its potential to suppress the pandemics is limited, highlighting the key role of vaccinations.

摘要

新冠病毒感染的免疫反应和特异性抗体产生是决定个体患者预后和全球控制大流行的关键因素之一。所谓的“暗数”,即已经感染但未被医疗系统登记的一部分人群,使得估计群体免疫和预测大流行轨迹变得困难。在这里,我们报告了一项针对从未被确诊过 SARS-CoV-2 感染的个体中隐匿性 SARS-CoV-2 群体免疫的人群筛查的后续研究;第一次筛查是在 2021 年 5 月,随访是在 2021 年 12 月。我们发现,5 月作为“暗数”检测到的针对 SARS-CoV-2 的特异性抗体,由于其显著下降,7 个月后不能被认为是重要的。另一方面,在第一次筛查中抗 SARS-CoV-2 IgG 阴性且从未被诊断为 SARS-CoV-2 感染或接种疫苗的参与者中,有 26%的人抗 SARS-CoV-2 IgG 呈阳性。这归因于波兰在 12 月研究前不久发生的最近的第四波大流行的“暗数”。然而,在 5 月至 12 月之间接种疫苗的参与者表现出的抗体水平高于那些经历轻度或无症状(因此未被登记)感染的参与者。只有 7%的这些接种疫苗的参与者表现出由感染引起的抗体(抗 NCP)。在 2021 年 5 月之前感染过 SARS-CoV-2 且在 5 月至 12 月之间完成全程接种的参与者中观察到了最高水平的保护。这些观察结果表明,隐匿性群体免疫的比例相当大,但它抑制大流行的潜力有限,突出了疫苗接种的关键作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be4a/9462561/5c9d488990c0/pone.0274095.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be4a/9462561/aafadfc15d3f/pone.0274095.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be4a/9462561/fee1a2ebd31a/pone.0274095.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be4a/9462561/5c9d488990c0/pone.0274095.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be4a/9462561/aafadfc15d3f/pone.0274095.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be4a/9462561/fee1a2ebd31a/pone.0274095.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be4a/9462561/5c9d488990c0/pone.0274095.g003.jpg

相似文献

1
Dynamics of anti-SARS-CoV-2 seroconversion in individual patients and at the population level.个体患者和人群水平抗 SARS-CoV-2 血清转化的动态。
PLoS One. 2022 Sep 9;17(9):e0274095. doi: 10.1371/journal.pone.0274095. eCollection 2022.
2
Hidden fraction of Polish population immune to SARS-CoV-2 in May 2021.2021 年 5 月波兰人群中对 SARS-CoV-2 具有免疫力的隐匿人群。
PLoS One. 2022 Feb 3;17(2):e0253638. doi: 10.1371/journal.pone.0253638. eCollection 2022.
3
The level of protective post-vaccination antibodies in NIPH-NIH employees after administration of Pfizer vaccine against COVID-19.辉瑞 COVID-19 疫苗接种后日本国立感染症研究所-国立卫生研究所员工的保护性疫苗接种后抗体水平。
Przegl Epidemiol. 2021;75(1):3-13. doi: 10.32394/pe.75.01.
4
[Shedding of SARS-CoV-2 Virus in COVID-19 Patients and Neutralizing Antibody Level].[新型冠状病毒肺炎患者严重急性呼吸综合征冠状病毒2病毒脱落情况及中和抗体水平]
Mikrobiyol Bul. 2022 Jul;56(3):416-431. doi: 10.5578/mb.20229704.
5
High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort.在巴西玛瑙斯市第二波疫情之前,高抗严重急性呼吸综合征冠状病毒 2 抗体血清转化率,以及社会行为措施的保护作用:前瞻性 DETECTCoV-19 队列研究结果。
Lancet Glob Health. 2021 Nov;9(11):e1508-e1516. doi: 10.1016/S2214-109X(21)00355-7.
6
Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?接种 COVID-19 疫苗后,人乳中能否检测到 SARS-CoV-2 抗体?
J Pediatric Infect Dis Soc. 2022 Apr 30;11(4):126. doi: 10.1093/jpids/piac024.
7
Serological investigation of asymptomatic cases of SARS-CoV-2 infection reveals weak and declining antibody responses.无症状 SARS-CoV-2 感染病例的血清学调查显示,抗体反应较弱且逐渐减弱。
Emerg Microbes Infect. 2021 Dec;10(1):905-912. doi: 10.1080/22221751.2021.1919032.
8
Comparison of Seroconversion in Children and Adults With Mild COVID-19.儿童和轻症 COVID-19 成人患者血清转换的比较。
JAMA Netw Open. 2022 Mar 1;5(3):e221313. doi: 10.1001/jamanetworkopen.2022.1313.
9
[Humoral Immune Response in Inactivated SARS-CoV-2 Vaccine: When Should a Booster Dose be Administered?].[灭活新型冠状病毒疫苗的体液免疫反应:何时应接种加强针?]
Mikrobiyol Bul. 2022 Jul;56(3):566-573. doi: 10.5578/mb.20229715.
10
[Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].[意大利北部皮埃蒙特大区博尔戈塞西亚人群中抗SARS-CoV-2 IgG/IgM抗体的血清流行率:封锁后时期的监测策略?]
Epidemiol Prev. 2020 Sep-Dec;44(5-6 Suppl 2):200-206. doi: 10.19191/EP20.5-6.S2.119.

引用本文的文献

1
Nasopharyngeal Viral Load Is the Major Driver of Incident Antibody Immune Response to SARS-CoV-2 Infection.鼻咽病毒载量是SARS-CoV-2感染后抗体免疫反应的主要驱动因素。
Open Forum Infect Dis. 2023 Dec 2;10(12):ofad598. doi: 10.1093/ofid/ofad598. eCollection 2023 Dec.
2
A Highly Sensitive Immunoassay for Determination of Immune Response to SARS-CoV-2 in Capillary Blood Samples.一种用于测定毛细血管血样中对SARS-CoV-2免疫反应的高灵敏度免疫测定法。
Biomedicines. 2022 Nov 11;10(11):2897. doi: 10.3390/biomedicines10112897.

本文引用的文献

1
Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico.墨西哥首次和二次疫情期间未接种疫苗人群的血清转换动态和 SARS-CoV-2 血清阳性率。
Sci Rep. 2022 Mar 28;12(1):5241. doi: 10.1038/s41598-022-09395-3.
2
Hidden fraction of Polish population immune to SARS-CoV-2 in May 2021.2021 年 5 月波兰人群中对 SARS-CoV-2 具有免疫力的隐匿人群。
PLoS One. 2022 Feb 3;17(2):e0253638. doi: 10.1371/journal.pone.0253638. eCollection 2022.
3
Antibodies specific to SARS-CoV-2 proteins N, S and E in COVID-19 patients in the normal population and in historical samples.
新型冠状病毒肺炎患者和历史样本中针对 SARS-CoV-2 蛋白 N、S 和 E 的抗体。
J Gen Virol. 2021 Nov;102(11). doi: 10.1099/jgv.0.001692.
4
Molnupiravir in COVID-19: A systematic review of literature.莫努匹韦治疗 COVID-19:文献系统评价。
Diabetes Metab Syndr. 2021 Nov-Dec;15(6):102329. doi: 10.1016/j.dsx.2021.102329. Epub 2021 Oct 30.
5
SARS-CoV-2 vaccine protection and deaths among US veterans during 2021.2021 年美国退伍军人中 SARS-CoV-2 疫苗保护作用和死亡情况。
Science. 2022 Jan 21;375(6578):331-336. doi: 10.1126/science.abm0620. Epub 2021 Nov 4.
6
IgG Antibodies Develop to Spike but Not to the Nucleocapsid Viral Protein in Many Asymptomatic and Light COVID-19 Cases.在许多无症状和轻症 COVID-19 病例中,针对刺突蛋白而不是核衣壳病毒蛋白产生 IgG 抗体。
Viruses. 2021 Sep 28;13(10):1945. doi: 10.3390/v13101945.
7
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months.辉瑞-BioNTech 新冠疫苗接种 6 个月后免疫体液反应逐渐减弱。
N Engl J Med. 2021 Dec 9;385(24):e84. doi: 10.1056/NEJMoa2114583. Epub 2021 Oct 6.
8
Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.COVID-19 患者症状出现后七个月内 SARS-CoV-2 特异性和中和抗体的动力学。
Microbiol Spectr. 2021 Oct 31;9(2):e0059021. doi: 10.1128/Spectrum.00590-21. Epub 2021 Sep 22.
9
Seroprevalence and levels of IgG antibodies after COVID-19 infection or vaccination.新冠病毒感染或接种疫苗后的血清抗体阳性率和水平。
Infect Dis (Lond). 2022 Jan;54(1):63-71. doi: 10.1080/23744235.2021.1974540. Epub 2021 Sep 14.
10
Differences in the Concentration of Anti-SARS-CoV-2 IgG Antibodies Post-COVID-19 Recovery or Post-Vaccination.新冠病毒感染康复后或接种疫苗后抗 SARS-CoV-2 IgG 抗体浓度的差异。
Cells. 2021 Jul 31;10(8):1952. doi: 10.3390/cells10081952.